Linezolid Injection, Solution
Product Images NDC 55150-242

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Linezolid (NDC 55150-242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Plasma Concentrations Of Linezolid In Adults At Steady-state Following Oral Dosing Every 12 Hours (mean ± Standard Deviation, N = 16) (Linezolid Fig1)

Figure 1. Plasma Concentrations Of Linezolid In Adults At Steady-state Following Oral Dosing Every 12 Hours (mean ± Standard Deviation, N = 16) (Linezolid Fig1)
This appears to be a graph depicting the plasma concentration of Linezolid in mcg/mL over a period of 12 hours after oral administration of 600mg every 12 hours. The x-axis measures the time in hours after administration, from 0 to 12 hours, while the y-axis measures the plasma concentration in mcg/mL, ranging from 4 to 12 mcg/mL.*
FDA Label Image

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))
This is a sterile medication product for intravenous administration consisting of Linezolid, dextrose, sodium citrate, citric acid, and water for injection. It comes in a 300 mL single-dose container with a concentration of 2mg/mL with a strength of 600mg per 300 mL. It is not recommended to add any other medication, and it can only be used with a calibrated infusion device. The solution may exhibit a yellow color that intensifies over time, but it should not affect its potency. This medication requires refrigeration under specific temperature conditions and must not be frozen. The product is manufactured in India and distributed by a company based in New Jersey.*
FDA Label Image

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))
This is a description for a medication called Linezolid, in the form of an injection, with a concentration of 600 mg per 300 mL. It is produced by a company called AUROMEDIC, and is meant for intravenous administration only. The medication comes in a single-dose container and should not be used in series connections. The container must be checked for leaks prior to usage. The prescription dosage should be followed as additional medications are not recommended. The medication should be stored at 20-25 degrees Celsius and the overwrap should be retained prior to use.*
FDA Label Image

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))

Package Label-principal Display Panel (600 mg per 300 mL (2 mg / mL))
This is a description of a medication called Linezolid. It is provided in single-dose containers containing 600mg per 300 mL, to be administered intravenously using a calibrated infusion device. The medication must be stored at 20°-25°C, and it is important to protect it from light before use. The accompanying prescribing information should be consulted to determine the proper dosage. The medication should not be used in series connections and supplementary medications should not be added. Checking for leaks is important, and if leaks are found, the medication should be discarded. The medication is distributed by AuroMedics Pharma LLC and produced in India.*
FDA Label Image

Linezolid Chemical Structure (Linezolid Str)

Linezolid Chemical Structure (Linezolid Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.